Morgan Stanley Amryt Pharma PLC Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$7.0 - $14.77 $17 Million - $35.8 Million	2,421,783 Added 2912.34%	2,504,939 $36.5 Million
Q4 2022 Feb 14, 2023	SELL	$6.68 - $7.58 $28,323 - $32,139	-4,240 Reduced 4.85%	83,156 $607,000
Q3 2022 Nov 14, 2022	BUY	$6.8 - $8.01 $5,854 - $6,896	861 Added 0.99%	87,396 $605,000
Q2 2022 Oct 27, 2022	BUY	$6.85 - $8.87 $48,073 - $62,249	7,018 Added 8.83%	86,535 $605,000
Q2 2022 Aug 15, 2022	BUY	$6.85 - $8.87 $48,073 - $62,249	7,018 Added 8.83%	86,535 $605,000
Q1 2022 Oct 27, 2022	SELL	$6.3 - $10.86 $44,213 - $76,215	-7,018 Reduced 8.11%	79,517 $658,000
Q1 2022 May 13, 2022	BUY	$6.3 - $10.86 $361,147 - $622,549	57,325 Added 258.31%	79,517 $658,000
Q4 2021 Feb 14, 2022	BUY	$9.44 - $12.24 $167,663 - $217,394	17,761 Added 400.84%	22,192 $240,000
Q3 2021 Nov 15, 2021	BUY	$9.63 - $12.47 $42,670 - $55,254	4,431 New	4,431 $53,000

142K

Ticker AMYT
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 64,177,000
Description
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.